Gluetacs Therapeutics, a ShanghaiTech University-spinout focusing on molecular glue and heterobifunctional degrader development, today announced that it has submitted an Investigational New Drug (IND) application to the Center For Drug Evaluation (CDE) requesting approval to initiate its first-in-human Phase 1 clinical trial of GT919 in patients with relapsed or refractory Non-Hodgkin Lymphoma.

"Submission of the GT929 clinical trial application to CDE based on the GLUETACS® platform is another momentous company milestone that represents years of research from academic pioneers and the tremendous focus and commitments of the team," said Dr Xiaobao Yang, Founder, Chairman and CEO of Gluetacs Therapeutics. "Besides GT919 and GT929, we have also seen great prospect of more candidates in our pipeline focusing on innovative targeted protein degradation therapies in areas with high unmet medical needs. We look forward to initiating Phase 1 study of GT929 and the collaboration with any potential partners. "